Effectiveness and Safety of Lanadelumab in the Treatment of Patients with Hereditary Angioedema in Routine Clinical Practice in the Russian Federation.

Tatiana Nekrasova 1 * , Liubov Aleshina 2, Elena Bobrikova 3, Ekaterina Viktorova 4, Elena Volkova 5, Elena Gracheva 6, Darya Demina 7, Olga Ivanitskaya 8, Marina Karakina 9, Natalia Kuzmenko 4, Irina Lyulyu 10, Irina Manto 11, Nikolay Nazarov 1, Dar’ya Fomina 12 13, Anna Shcherbina 4, Tatiana Latysheva 1, Elena Latysheva 1
More Detail
1 Department of Immunopathology, National Research Center – Institute of Immunology Federal Medical-Biological Agency, Moscow, Russia
2 Department of Clinical Immunology and Allergology, Saratov State Medical University named after V.I. Razumovsky, Saratov, Russia
3 Moscow City Research and Practical Center of Allergy and Immunology, City Clinical Hospital 52, Moscow Healthcare Department, Moscow, Russia
4 Department of Clinical Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
5 Department of Allergology and Immunology, Smolensk Clinical Hospital №1, Regional Center of Allergology and Immunology, Smolensk, Russian Federation
6 Counselling outpatient clinic, Vologda regional clinical hospital, Vologda, Russian Federation
7 Department of Allergology, Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation
8 Department of Clinical Medicine, Murmansk Arctic University, Murmansk, Russian Federation
9 Consultative and diagnostic department, Sverdlovsk Regional Clinical Hospital, Ekaterinburg, Russian Federation
10 Department of Pulmonology, Republican Hospital named after V.A. Baranov, Petrozavodsk, Republic of Karelia, Russian Federation
11 Clinical and diagnostic department, DOCMED clinic
12 Moscow City Research and Practical Center of Allergy and Immunology, City Clinical Hospital 52, Moscow Healthcare Department, Moscow, Russian Federation
13 Department of Clinical Immunology and Allergy, The First Sechenov State Medical University, Moscow, Russia
* Corresponding Author
J CLIN MED KAZ, Volume 23, Issue 4, pp. 14-24. https://doi.org/10.23950/jcmk/18883
OPEN ACCESS 329 Views 112 Downloads
Download Full Text (PDF)
Author Contributions: Conceptualization, methodology, supervision – E. L. and T. L.; E. L. and I. M. and E. B. and D. F., E.V. and E. G. and L. A. and D. D. and E. V. and O. I. and M. K. and N. K. and I. L. and N. N. and T. N. ― investigation, resources; I. M. ― project administration, data curation, validation, formal analysis; E. L. and I. M. ― writing – original draft preparation; E. L. and T. L. and A. S. ― writing – review and editing. All authors have read and agreed to the published version of the manuscript.  

Data availability statement: All raw data underlying the findings of this study can be obtained from the corresponding author upon reasonable request.

Artificial Intelligence (AI) Disclosure Statement: Artificial intelligence was used to translate and edit the text to improve its readability in English, ensure efficient work under human supervision.

ABSTRACT

Background: Hereditary angioedema (HAE) caused by C1 inhibitor deficiency is a rare condition marked by recurrent swelling of the skin and mucous membranes. This study evaluated the effectiveness and safety of lanadelumab in routine clinical practice in Russia (IISR-2021-200085).
Methods: A prospective cohort of 30 individuals with HAE was observed. Most patients were women (87%), with a mean age of 34 years; Seventeen percent of participants were adolescents. Prior to initiating lanadelumab, 16 patients (53%) had been receiving long-term prophylaxis, which was discontinued once lanadelumab was started. Treatment outcomes were assessed by comparing attack frequency, medication use for acute events, disease control scores, and quality of life before and after lanadelumab therapy.
Results: Before treatment, patients reported an average of 8.6 attacks per month. After 6 months of lanadelumab treatment, the mean attack frequency was reduced to 0.5 per month (p < 0.001). Use of acute therapies decreased from 4.73 to 0.43 doses per month (p < 0.001). Disease control improved substantially, and quality-of-life scores improved from 58.2 to 25.3 points (p < 0.001). No significant lanadelumab-related adverse events were observed.
Conclusion: In routine clinical practice, lanadelumab proved highly effective in reducing attack rates, enhancing disease control, and improving quality of life in patients with hereditary angioedema. The therapy was well tolerated, with no serious safety concerns identified. These findings reinforce lanadelumab as a reliable long-term prophylactic option for hereditary angioedema management.
Keywords: hereditary angioedema, HAE, angioedema, C1-inhibitor, bradykinin, lanadelumab

CITATION

Nekrasova T, Aleshina L, Bobrikova E, Viktorova E, Volkova E, Gracheva E, et al. Effectiveness and Safety of Lanadelumab in the Treatment of Patients with Hereditary Angioedema in Routine Clinical Practice in the Russian Federation.. J CLIN MED KAZ. 2026;23(4):14-24. https://doi.org/10.23950/jcmk/18883

REFERENCES

  • Aygören-pürsün E, Magerl M, Maetzel A, Maurer M. Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis. 2018; May 4;13(1): 1–9. https://doi.org/10.1186/s13023-018-0815-5.
  • Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, Caballero T, Farkas H, Grumach A, Kaplan AP, Riedl MA, Triggiani M, Zanichelli A, Zuraw B; HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology). Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014: May; 69(5):602-616. https://doi.org/10.1111/all.12380.
  • Bliznetz EA, Viktorova EA, Vishneva EA, Dzobava EM, Il’ina NI, Kuzmenko NB, Latysheva EA, Latysheva TV, Manto IA, Namazova-Baranova LS, Nenasheva NM, Pampura AN, Polyakov AV, Selimzianova LR, Shcherbina AY. Hereditary angioedema. Clinical Guidelines (D84.1). Russian Journal of Allergy. 2021;18(2):77–114.
  • Li HH, Mycroft S, Christiansen S, Wood DN, Feuersenger H, Pawaskar D, Jacobs I. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial. Allergy Asthma Proc. 2018 Sep 14;39(5):365-370. https://doi.org/10.2500/aap.2018.39.4164.
  • Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, Busse PJ, Anderson J, Magerl M, Martinez-Saguer I, Davis-Lorton M, Zanichelli A, Li HH, Craig T, Jacobs J, Johnston DT, Shapiro R, Yang WH, Lumry WR, Manning ME, Schwartz LB, Shennak M, Soteres D, Zaragoza-Urdaz RH, Gierer S, Smith AM, Tachdjian R, Wedner HJ, Hebert J, Rehman SM, Staubach P, Schranz J, Baptista J, Nothaft W, Maurer M; HELP Investigators. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. JAMA. 2018 Nov 27;320(20):2108-2121. https://doi.org/10.1001/jama.2018.16773. Erratum in: JAMA. 2019 Apr 23;321(16):1636. https://doi.org/10.1001/jama.2019.4254.
  • Riedl MA, Bernstein JA, Craig T, Banerji A, Magerl M, Cicardi M, Longhurst HJ, Shennak MM, Yang WH, Schranz J, Baptista J, Busse PJ. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension. Clin Transl Allergy. 2017 Oct 6(7):36. https://doi.org/10.1186/s13601-017-0172-9.
  • Banerji A, Bernstein JA, Johnston DT, Lumry WR, Magerl M, Maurer M, Martinez-Saguer I, Zanichelli A, Hao J, Inhaber N, Yu M, Riedl MA; HELP OLE Investigators. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. Allergy. 2022 Mar;77(3):979-990. https://doi.org/10.1111/all.15011.
  • Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygören-Pürsün E, Banerji A, Bara NA, Boccon-Gibod I, Bork K, Bouillet L, Boysen HB, Brodszki N, Busse PJ, Bygum A, Caballero T, Cancian M, Castaldo A, Cohn DM, Csuka D, Farkas H, Gompels M, Gower R, Grumach AS, Guidos-Fogelbach G, Hide M, Kang HR, Kaplan AP, Katelaris C, Kiani-Alikhan S, Lei WT, Lockey R, Longhurst H, Lumry WR, MacGinnitie A, Malbran A, Martinez Saguer I, Matta JJ, Nast A, Nguyen D, Nieto-Martinez SA, Pawankar R, Peter J, Porebski G, Prior N, Reshef A, Riedl M, Ritchie B, Rafique Sheikh F, Smith WB, Spaeth PJ, Stobiecki M, Toubi E, Varga LA, Weller K, Zanichelli A, Zhi Y, Zuraw B, Craig T. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022 Jul;77(7):1961-1990. https://doi.org/10.1111/all.15214.
  • Latysheva E, Latysheva T, Bodnya O, Demina D, Kuzmenko N, Fedotova N, Pampura A, Fomina D, Ukhanova O, Sizyakina L, Totolian A, Milichkina A. Resolution on the results of the Council of Experts on the Long-term Prophylaxis of Hereditary Angioedema in Russia [in Russian]. Russian Journal of Allergy. 2021; 18(3):126–130.
  • Clinical Guidelines. Hereditary angioedema, [Internet]. 2024 [cited 2023 Aug 12] Avaliable from: https://cr.minzdrav.gov.ru/view-cr/267_2.
  • Riedl MA, Maurer M, Bernstein JA, Banerji A, Longhurst HJ, Li HH, Lu P, Hao J, Juethner S, Lumry WR; HELP Investigators. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy. 2020 Nov;75(11):2879-2887. https://doi.org/10.1111/all.14416.
  • Tachdjian R, Banerji A, Busse PJ, Agmon-Levin N, Anderson J, Cancian M, Spadaro G, Enciu C, Estepan DN, Khutoryansky N, Jain S, Recke A. Effective long-term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER/ENABLE. Pediatr Allergy Immunol. 2025 Apr;36(4):e70072. https://doi.org/10.1111/pai.70072.
  • Dorr AD, Chopra C, Coulter TI, Dempster J, Dziadzio M, El-Shanawany T, Garcez T, Gompels M, Herriot R, Jain R, Levi M, Lorenzo L, Makki I, Mapazire E, Murng SHK, Noorani S, Savic S, Steele CL, Symons C, Tarzi M, Yong PFK, Kiani-Alikhan S. Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit. Allergy. 2023 May;78(5):1369-1371. https://doi.org/10.1111/all.15620.
  • Martinez-Saguer I, Knop J, Flemming A, Thomann M, Maurer M. Real World treatment patterns of hereditary angioedema with lanadelumab in Germany: A prescription data analysis. J Dtsch Dermatol Ges. 2022 Aug;20(8):1127-1129. https://doi.org/10.1111/ddg.14785.
  • Fain O, Du-Thanh A, Gobert D, Launay D, Inhaber N, Boudjemia K, Aubineau M, Sobel A, Boccon-Gibod I, Weiss L, Bouillet L. Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France. Allergy Asthma Clin Immunol. 2022 Apr 1;18(1):30. https://doi.org/10.1186/s13223-022-00664-4.
  • Iaboni A, Kanani A, Lacuesta G, Song C, Kan M, Betschel SD. Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada. Allergy Asthma Clin Immunol. 2021 Jul 23;17(1):78. https://doi.org/10.1186/s13223-021-00579-6.
  • Weller K, Magerl M, Peveling-Oberhag A, Martus P, Staubach P, Maurer M. The Angioedema Quality of Life Questionnaire (AE-QoL) - assessment of sensitivity to change and minimal clinically important difference. Allergy. 2016 Aug;71(8):1203-9. https://doi.org/10.1111/all.12900.
  • Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, Metz M, Staubach P, Maurer M. Development, validation, and initial results of the Angioedema Activity Score. Allergy. 2013 Sep;68(9):1185-92. https://doi.org/10.1111/all.12209.
  • Forjaz MJ, Ayala A, Caminoa M, Prior N, Pérez-Fernández E, Caballero T; DV-HAE-QoL Study Group. HAE-AS: A Specific Disease Activity Scale for Hereditary Angioedema With C1-Inhibitor Deficiency. J Investig Allergol Clin Immunol. 2021 Jun 22;31(3):246-252. https://doi.org/10.18176/jiaci.0479.
  • Weller K, Donoso T, Magerl M, Aygören-Pürsün E, Staubach P, Martinez-Saguer I, Hawro T, Altrichter S, Krause K, Siebenhaar F, Metz M, Zuberbier T, Freier D, Maurer M. Validation of the Angioedema Control Test (AECT)-A Patient-Reported Outcome Instrument for Assessing Angioedema Control. J Allergy Clin Immunol Pract. 2020 Jun;8(6):2050-2057.e4. https://doi.org/10.1016/j.jaip.2020.02.038.
  • Bygum A, Busse P, Caballero T, Maurer M. Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema. Front Med (Lausanne). 2017 Dec 4;(4):1-7. https://doi.org/10.3389/fmed.2017.00212.
  • Buttgereit T, Vera C, Weller K, Gutsche A, Grekowitz EM, Aykanat S, Wahn V, Krüger R, Maurer M, Magerl M. Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study. J Allergy Clin Immunol Pract. 2021 Oct;9(10):3744-3751. https://doi.org/10.1016/j.jaip.2021.04.072.
  • Abuzakouk M, Ghorab O, Al-Hameli H, Salvo F, Grandon D, Maurer M. Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience. World Allergy Organ J. 2022 Jul 12;15(7):100-664. https://doi.org/10.1016/j.waojou.2022.100664.
  • Maurer M, Magerl M. Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives. J Dtsch Dermatol Ges. 2011 Feb;9(2):99-107. English, German. https://doi.org/10.1111/j.1610-0387.2010.07546.x.
  • Martinez-Saguer I, Knop J, Flemming A, Thomann M, Maurer M. Real World treatment patterns of hereditary angioedema with lanadelumab in Germany: A prescription data analysis. J Dtsch Dermatol Ges. 2022 Aug;20(8):1127-1129. https://doi.org/10.1111/ddg.14785.